Literature DB >> 26780619

Implementation of the European multicentre database of healthy controls for [(123)I]FP-CIT SPECT increases diagnostic accuracy in patients with clinically uncertain parkinsonian syndromes.

Nathalie L Albert1, Marcus Unterrainer2, Markus Diemling3, Guoming Xiong2, Peter Bartenstein2, Walter Koch2, Andrea Varrone4, John C Dickson5, Livia Tossici-Bolt6, Terez Sera7, Susanne Asenbaum8, Jan Booij9, L Özlem Atay Kapucu10, Andreas Kluge11, Morten Ziebell12, Jacques Darcourt13, Flavio Nobili14, Marco Pagani15,16, Osama Sabri17, Swen Hesse17,18, Thierry Vander Borght19, Koen Van Laere20, Klaus Tatsch21, Christian la Fougère22.   

Abstract

PURPOSE: Even though [(123)I]FP-CIT SPECT provides high accuracy in detecting nigrostriatal cell loss in neurodegenerative parkinsonian syndromes (PS), some patients with an inconclusive diagnosis remain. We investigated whether the diagnostic accuracy in patients with clinically uncertain PS with previously inconclusive findings can be improved by the use of iterative reconstruction algorithms and an improved semiquantitative evaluation which additionally implemented a correction algorithm for patient age and gamma camera dependency (EARL-BRASS; Hermes Medical Solutions, Sweden).
METHODS: We identified 101 patients with inconclusive findings who underwent an [(123)I]FP-CIT SPECT between 2003 and 2010 as part of the diagnostic process of suspected PS at the University of Munich, and re-evaluated these scans using iterative reconstruction algorithms and the new corrected EARL-BRASS. Clinical follow-up was obtained in 62 out of the 101 patients and constituted the gold standard for the re-evaluation to assess the possible improvement in diagnostic accuracy.
RESULTS: Clinical follow-up confirmed the diagnosis of PS in 11 of the 62 patients. In patients in whom both visual and semiquantitative analysis showed concordant findings (48 patients), a high negative predictive value (93 %), positive predictive value (100 %) and accuracy (94 %) were found, and thus a correct diagnosis was obtained in 45 of the 48 patients. Among the 14 patients with discordant findings, the additional semiquantitative analysis correctly identified all five of nine patients patients without PS by nonpathological semiquantitative findings in visually pathological or inconclusive scans. In contrast, four of the remaining five patients with decreased semiquantitative values but visually normal scans did not show a PS during follow-up.
CONCLUSION: The age-corrected and camera-corrected mode of evaluation using EARL-BRASS provided a notable improvement in the diagnostic accuracy of [(123)I]FP-CIT SPECT in PS patients with previously inconclusive findings. The gain in accuracy might be achieved by better discrimination between physiological low striatal [(123)I]FP-CIT binding due to age-related loss of the dopamine transporter or pathological loss of binding.

Entities:  

Keywords:  Diagnostic accuracy; EARL-BRASS; Parkinsonian syndromes; [123I]FP-CIT SPECT

Mesh:

Substances:

Year:  2016        PMID: 26780619     DOI: 10.1007/s00259-015-3304-2

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  25 in total

1.  Combined 123I-FP-CIT and 123I-IBZM SPECT for the diagnosis of parkinsonian syndromes: study on 72 patients.

Authors:  M Plotkin; H Amthauer; S Klaffke; A Kühn; L Lüdemann; G Arnold; K-D Wernecke; A Kupsch; R Felix; S Venz
Journal:  J Neural Transm (Vienna)       Date:  2004-09-14       Impact factor: 3.575

2.  Loss of dopamine transporter binding in Parkinson's disease follows a single exponential rather than linear decline.

Authors:  Johannes Schwarz; Alexander Storch; Walter Koch; Oliver Pogarell; Perry E Radau; Klaus Tatsch
Journal:  J Nucl Med       Date:  2004-10       Impact factor: 10.057

3.  The SCL-90 and the MMPI: a step in the validation of a new self-report scale.

Authors:  L R Derogatis; K Rickels; A F Rock
Journal:  Br J Psychiatry       Date:  1976-03       Impact factor: 9.319

4.  Accurate differentiation of parkinsonism and essential tremor using visual assessment of [123 I]-FP-CIT SPECT imaging: The [123 I]-FP-CIT study group.

Authors:  Hani T S Benamer; Jim Patterson; Donald G Grosset; J Booij; K de Bruin; E van Royen; J D Speelman; M H I M Horstink; H J W A Sips; R A Dierckx; J Versijpt; D Decoo; C Van Der Linden; D M Hadley; M Doder; A J Lees; D C Costa; S Gacinovic; W H Oertel; O Pogarell; H Hoeffken; K Joseph; K Tatsch; J Schwarz; V Ries
Journal:  Mov Disord       Date:  2000-05       Impact factor: 10.338

5.  Striatal dopamine transporter binding in early to moderately advanced Parkinson's disease: monitoring of disease progression over 2 years.

Authors:  M Chouker; K Tatsch; R Linke; O Pogarell; K Hahn; J Schwarz
Journal:  Nucl Med Commun       Date:  2001-06       Impact factor: 1.690

6.  Automatic 3D intersubject registration of MR volumetric data in standardized Talairach space.

Authors:  D L Collins; P Neelin; T M Peters; A C Evans
Journal:  J Comput Assist Tomogr       Date:  1994 Mar-Apr       Impact factor: 1.826

7.  Distinguishing SWEDDs patients with asymmetric resting tremor from Parkinson's disease: a clinical and electrophysiological study.

Authors:  Petra Schwingenschuh; Diane Ruge; Mark J Edwards; Carmen Terranova; Petra Katschnig; Fatima Carrillo; Laura Silveira-Moriyama; Susanne A Schneider; Georg Kägi; Francisco J Palomar; Penelope Talelli; John Dickson; Andrew J Lees; Niall Quinn; Pablo Mir; John C Rothwell; Kailash P Bhatia
Journal:  Mov Disord       Date:  2010-04-15       Impact factor: 10.338

8.  Extrastriatal binding of [¹²³I]FP-CIT in the thalamus and pons: gender and age dependencies assessed in a European multicentre database of healthy controls.

Authors:  Walter Koch; Marcus Unterrainer; Guoming Xiong; Peter Bartenstein; Markus Diemling; Andrea Varrone; John C Dickson; Livia Tossici-Bolt; Terez Sera; Susanne Asenbaum; Jan Booij; Ozlem L Kapucu; Andreas Kluge; Morten Ziebell; Jacques Darcourt; Flavio Nobili; Marco Pagani; Swen Hesse; Thierry Vander Borght; Koen Van Laere; Klaus Tatsch; Christian la Fougère
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-05-08       Impact factor: 9.236

Review 9.  Role of DAT-SPECT in the diagnostic work up of parkinsonism.

Authors:  Christoph Scherfler; Johannes Schwarz; Angelo Antonini; Donald Grosset; Francesc Valldeoriola; Kenneth Marek; Wolfgang Oertel; Eduardo Tolosa; Andrew J Lees; Werner Poewe
Journal:  Mov Disord       Date:  2007-07-15       Impact factor: 10.338

10.  Accuracy of DaTSCAN (123I-Ioflupane) SPECT in diagnosis of patients with clinically uncertain parkinsonism: 2-year follow-up of an open-label study.

Authors:  Eduardo Tolosa; Thierry Vander Borght; Emilio Moreno
Journal:  Mov Disord       Date:  2007-12       Impact factor: 10.338

View more
  16 in total

Review 1.  Nuclear Imaging in the Diagnosis of Clinically Uncertain Parkinsonian Syndromes.

Authors:  Ralph Buchert; Carsten Buhmann; Ivayla Apostolova; Philipp T Meyer; Jürgen Gallinat
Journal:  Dtsch Arztebl Int       Date:  2019-11-01       Impact factor: 5.594

2.  Visual versus automated analysis of [I-123]FP-CIT SPECT scans in parkinsonism.

Authors:  Elina Mäkinen; Juho Joutsa; Jarkko Johansson; Maija Mäki; Marko Seppänen; Valtteri Kaasinen
Journal:  J Neural Transm (Vienna)       Date:  2016-06-20       Impact factor: 3.575

3.  Automatic classification of dopamine transporter SPECT: deep convolutional neural networks can be trained to be robust with respect to variable image characteristics.

Authors:  Markus Wenzel; Fausto Milletari; Julia Krüger; Catharina Lange; Michael Schenk; Ivayla Apostolova; Susanne Klutmann; Marcus Ehrenburg; Ralph Buchert
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-08-31       Impact factor: 9.236

4.  Decoding the dopamine transporter imaging for the differential diagnosis of parkinsonism using deep learning.

Authors:  Yu Zhao; Jianjun Wu; Ping Wu; Matthias Brendel; Jiaying Lu; Jingjie Ge; Chunmeng Tang; Jimin Hong; Qian Xu; Fengtao Liu; Yimin Sun; Zizhao Ju; Huamei Lin; Yihui Guan; Claudio Bassetti; Markus Schwaiger; Sung-Cheng Huang; Axel Rominger; Jian Wang; Chuantao Zuo; Kuangyu Shi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2022-05-19       Impact factor: 10.057

5.  Analysis of the Effect of Dopamine Transporter Scan on the Diagnosis and Management in a Tertiary Neurology Center.

Authors:  Shakya Bhattacharjee; Vijayashankar Paramanandam; Atrayee Bhattacharya
Journal:  Neurohospitalist       Date:  2019-02-14

6.  Impact of age and sex correction on the diagnostic performance of dopamine transporter SPECT.

Authors:  Helen Schmitz-Steinkrüger; Catharina Lange; Ivayla Apostolova; Franziska L Mathies; Lars Frings; Susanne Klutmann; Sabine Hellwig; Philipp T Meyer; Ralph Buchert
Journal:  Eur J Nucl Med Mol Imaging       Date:  2020-10-31       Impact factor: 9.236

Review 7.  Dopamine transporter SPECT imaging in Parkinson’s disease and parkinsonian disorders

Authors:  Ümit Özgür Akdemir; Ayşe Bora Tokçaer; Lütfiye Özlem Atay
Journal:  Turk J Med Sci       Date:  2021-04-30       Impact factor: 0.973

8.  Single-site 123I-FP-CIT reference values from individuals with non-degenerative parkinsonism-comparison with values from healthy volunteers.

Authors:  Rachid Fahmi; Günther Platsch; Alexandre Bani Sadr; Sylvain Gouttard; Stephane Thobois; Sven Zuehlsdorff; Christian Scheiber
Journal:  Eur J Hybrid Imaging       Date:  2020-03-13

9.  Comparison of machine learning and semi-quantification algorithms for (I123)FP-CIT classification: the beginning of the end for semi-quantification?

Authors:  Jonathan Christopher Taylor; John Wesley Fenner
Journal:  EJNMMI Phys       Date:  2017-11-29

10.  The impact of reconstruction and scanner characterisation on the diagnostic capability of a normal database for [123I]FP-CIT SPECT imaging.

Authors:  John C Dickson; Livia Tossici-Bolt; Terez Sera; Jan Booij; Morten Ziebell; Silvia Morbelli; Susanne Assenbaum-Nan; Thierry Vander Borght; Marco Pagani; Ozlem L Kapucu; Swen Hesse; Koen Van Laere; Jacques Darcourt; Andrea Varrone; Klaus Tatsch
Journal:  EJNMMI Res       Date:  2017-01-24       Impact factor: 3.138

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.